L'intérêt à découvert pour SuRo Capital donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de SuRo Capital. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

SuRo Capital (NASDAQ:SSSS) Stock, Rapport sur les intérêts à découvert

SURO CAPITAL CORP

SuRo Capital

SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.

SuRo Capital Corp

SuRo Capital Corp. - 6.00% Notes due 2026

CNBC&#8217;s Jim Cramer has weighed in on pre-market decline, attributing downward pressure to the &#8220;profit-takers&#8221; who bought the dip amid the ongoing selloff.
What Happened: In a recent post on X, the host of &#8220;Mad Money&#8221; also shed light on the crucial decision facing short sellers as they evaluate their next moves on prominent technology stocks like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
Cramer&#8217;s commentary suggests that after a surge in these heavily watched stocks on Wednesday, investors who bought in earlier are now looking to lock in their profits, naturally leading to some selling pressure before the trading day begins.
However, the tweet also delves into the strategic considerations of short sellers. These investors, who bet on stock prices declining, are currently at a crossroads. They are actively &#8220;trying to figure whether to operate on Nvidia, AVGO, AAPL all over again,&#8221; said Cramer.
The factors considered by short sellers to short a company&#8217;s stock include;
<ul>
<li>Assessment of the fundamental reasons for a negative outlook on these companies and whether they still hold true.</li>
</ul>
<ul>
<li>Are there new catalysts for a potential price decline?</li>
</ul>
<ul>
<li>Or, have the stocks demonstrated enough underlying strength to make further shorting a risky endeavor?</li>
</ul>
Cramer hints at the complexities facing the shorts, suggesting it might be &#8220;too difficult&#8221; to initiate or add to short positions as President Donald Trump paused the tariffs for 90 days on Wednesday. While Thursday&#8217;s decline could just entail profit taking, the short sellers need to beware of a possible &#8216;short squeeze&#8217; in the event of a further advance in these stocks, after the tariff pause move.
Cramer indicated that clarity on this dynamic would emerge relatively quickly, stating, &#8220;We will know by mid-morning.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">So now the profit-takers come in and the shorts are trying to figure whether to operate on Nvidia, AVGO, AAPL all over <a href="https://t.co/1AHRVjG6xe">https://t.co/1AHRVjG6xe</a>.&#8211;or it is too difficult and it is time to cover and move on,, We will know by mid morning&#8230; Watch the club ten minute broadcast at…
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1910265126713700434?ref_src=twsrc%5Etfw">April 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/government/regulations/25/04/44730455/bearish-sentiment-hits-7-week-high-mimicking-35-year-old-record-which-marked-the-bottom-of">Bearish Sentiment Hits 7-Week High, Mimicking 35-Year Old Record Which Marked The Bottom Of The October 1990 Bear Market</a>
Why It Matters: Tech giants have been hit the hardest in 2025, and Trump&#8217;s decision to levy tariffs on U.S. trading partners has further exacerbated a decline in these stocks.
Here is how the Magnificent 7 stocks performed on a year-to-date basis and after yesterday&#8217;s recovery.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>Thursday&#8217;s Premarket</td>
<td>Wednesday&#8217;s Performance</td>
<td>YTD Performance</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>-2.97%</td>
<td>18.72%</td>
<td>-17.34%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-2.38%</td>
<td>15.33%</td>
<td>-18.45%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>-1.24%</td>
<td>10.13%</td>
<td>-6.71%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-1.97%</td>
<td>11.98%</td>
<td>-13.22%</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-1.38%</td>
<td>9.88%</td>
<td>-15.51%</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-2.45%</td>
<td>14.76%</td>
<td>-2.25%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>-3.05%</td>
<td>22.69%</td>
<td>-28.23%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The market rebounded on Wednesday as the Nasdaq 100 climbed out of bear market territory, although it remained 13.85% below its prior peak of 22,222.61 points. The S&amp;P 500 was still in a correction, sitting 11.23% lower than its record high of 6,147.43 points, while the Dow Jones was 9.91% down from its 52-week high of 45,073.63 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Thursday. The SPY was down 2.40% to $535.43, while the QQQ declined 1.81% to $457.56, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44728276/spy-qqq-call-volumes-spiked-minutes-before-tariff-pause-announcement-alexandria-ocasio-cor" target="_blank" rel="noreferrer noopener">SPY, QQQ Call Volumes Spiked Minutes Before Tariff Pause Announcement: Alexandria Ocasio-Cortez Demands Disclosure From Congress Members</a></li>
</ul>
Photo by s_bukley on Shutterstock

Analyst Color

Equities

News

Markets

Analyst Ratings

General

AAPL

AMZN

AVGO

GOOG

MSFT

NVDA

TSLA

Jim Cramer Says Pre-Market Slide Driven By Profit-Takers: 'Shorts Are Trying To Figure Whether To Operate On Nvidia, AVGO, AAPL'

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54236430&amp;newsitemid=20250410722324&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=669a0b4f7c28dff1e1f2dd155328db75">Laser Photonics Corporation</a> (LPC) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading developer of laser systems for cleaning and other material processing applications, today announced an update on its strategic direction, which will be more focused on vertical integration and targeted acquisitions with the goal of positioning the company for sustainable growth regardless of potential market disruptions from tariffs and policy changes.
"Our strategic evolution toward vertical integration represents a fundamental shift in how we approach manufacturing and innovation," said John Armstrong, Executive Vice President of Laser Photonics. "By bringing more of our production capabilities in-house and acquiring complementary businesses like CMS with recession-resistant product lines, we're building a more resilient operation that can adapt quickly to changing market conditions while maintaining our competitive edge in quality and performance."
The company's vertical integration strategy is aimed at reducing dependency on external suppliers to decrease production costs and provide greater control over quality assurance and production timelines. This approach is expected to help streamline operations and improve margins over time.
The acquisition of Control MicroSystems' assets further enhanced LPC's portfolio with recession-resistant product lines that serve essential industries such as pharmaceuticals, which have historically maintained demand even during economic downturns, providing LPC with more stable revenue streams and reduced vulnerability to cyclical market fluctuations.
Navigating Trade Policy and Tariff Impacts
LPC management believes currently proposed U.S. trade policies could benefit domestic laser technology manufacturers by limiting the influx of low-cost, unregulated Chinese products that have previously found their way into the lower end of the market. As these policies evolve, the company's domestic manufacturing capabilities position it to capitalize on potential shifts in supply chains and customer preferences for American-made industrial laser systems.
Armstrong added, "While trade policies and tariffs create uncertainty for many in our industry, especially over the near-term, our strategic positioning will ideally enable us to view these changes as potential opportunities. Our commitment to American manufacturing excellence, combined with our expanded capabilities through vertical integration, means we will be able to offer customers high quality products with consistency."
The company's investment in domestic production capabilities also aligns with growing customer preferences for shorter supply chains and reduced geopolitical risk, trends that have accelerated following recent global supply chain disruptions and U.S. policy changes.
Long-Term Growth Outlook
LPC expects its strategic initiatives to drive sustainable growth regardless of macroeconomic conditions. The Company projects that its expanded product portfolio, enhanced by the CMS acquisition, has increased its total addressable market to around $45 billion while providing greater diversification across customer segments and industries.
Armstrong concluded, "We're building a company that's designed to thrive in both favorable and challenging economic environments. Our strategy isn't just about weathering potential storms…it's about positioning LPC to capitalize on opportunities that emerge from market disruptions while delivering consistent value to our customers and shareholders."

LASE

Laser Photonics Eyes $45B Market with CMS Deal and US Manufacturing Push for Long-Term Expansion

Mobilicom Gets Initial Production Scale Orders from Tier-1 Asia-Based Robotics Manufacturer

Needham analyst Mike Matson reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) from Hold to Hold.

Reiteration

MASI

Needham Reiterates Hold on Masimoto Hold

Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company's novel Optejet UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets.
Eyenovia continues to advance the Optejet UFD through Verification &amp; Validation (V&amp;V) studies to ensure that the device meets the standards around intended use and customer requirements. As of today, the Company has completed the following parameters:
<ul>
<li>Physical requirements such as dimensions and weight, and presence and operation of various light indicators</li>
<li>Usability requirements identified, including forces required to actuate the device or connect and disconnect the cartridge</li>
<li>Dosing performance, with consistency in delivering ophthalmic liquids to within a standard deviation of 1 microliter.</li>
<li>Longevity testing demonstrating that the device can operate without failure for the intended life span and with a sufficient safety factor.
<ul>
<li>In particular, tested key components more than 30,000 times, and demonstrated that the device can precisely dispense the ophthalmic solution well beyond 30,000 actuations.</li>
</ul>
</li>
<li>Safety testing of the base according to recognized standards, such as IEC 60601, to ensure performance specifications are met. This testing includes, among other things, electromagnetic interference, compatibility, and electrostatic discharge testing.
<ul>
<li>The Optejet UFD has satisfactorily met all requirements.</li>
</ul>
</li>
</ul>

EYEN

Eyenovia Advances User-Filled Optejet Toward Market with Strong Safety and Dosing Results

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $15 price target.

Price Target

BCRX

Needham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target

Banks typically keep day-to-day transactions under wraps, but large or repeated deposits can spark mandatory reporting to the Internal Revenue Service (IRS). If you've just deposited a sizable check or cash sum, here's what you should keep in mind before you assume your finances stay hidden.
<h3 class="wp-block-heading">The Threshold</h3>
Under the Bank Secrecy Act, financial institutions <a href="https://www.fincen.gov/sites/default/files/shared/CTRPamphlet.pdf">must report</a> deposits exceeding $10,000. This requirement applies to single transactions or multiple deposits on the same day that add up to $10,000 or more. In these scenarios, banks file IRS Form 8300 or submit the information electronically within 15 days. They also complete FinCEN <a href="https://www.irs.gov/pub/irs-tege/fin104_ctr.pdf">Form 104</a>, known as the Currency Transaction Report (CTR). These measures aim to spot potential money laundering or other financial crimes.
Deposits below $10,000 generally remain unreported, but banks can still file "suspicious activity" reports if they notice unusual patterns. For instance, making frequent $2,000 deposits might raise eyebrows if they appear inconsistent with your stated income. Since each bank sets its own protocols, it pays to ask how your institution handles borderline transactions.
See also: <a href="https://www.benzinga.com/markets/25/04/44730454/mark-cuban-reacts-to-trumps-tariff-turmoil-elections-have-consequences-while-market-chaos-continues">Mark Cuban Reminds Americans: &#8216;Elections Have Consequences&#8217; Amid Trump Tariff Push</a>
<h3 class="wp-block-heading">How Does The IRS Use The Information</h3>
Although the IRS doesn't disclose its full procedure for handling CTRs, officials do note that these documents may guide decisions about deeper audits, lead to questions about unexplained cash flows, and uncover unreported income. The agency's prime directive is tax collection, meaning it can pursue further inquiries if it suspects tax evasion or other illicit behavior.
<h3 class="wp-block-heading">When the IRS Might Peek</h3>
If you're under audit or owe back taxes, the IRS <a href="https://www.irs.gov/businesses/small-businesses-self-employed/audits-records-request">might request</a> your bank records. While the agency can't directly access your accounts, it can subpoena bank statements if it suspects unreported funds. In short, if your deposits don't match your reported income, be prepared to explain any discrepancies.
Featured image via Shutterstock
Read next: <a href="https://www.benzinga.com/government/regulations/25/04/44730455/bearish-sentiment-hits-7-week-high-mimicking-35-year-old-record-which-marked-the-bottom-of-the-october-1990-bear-market">Bearish Sentiment Hits 7-Week High, Mimicking 35-Year Old Record Which Marked The Bottom Of The October 1990 Bear Market</a>

Government

Regulations

Personal Finance

When Are Your Deposits Flagged? Understanding How And Why Banks Report Transactions To The IRS

LOVE

The Lovesac Company Sees FY26 Net Sales Of $700M-$750M Vs. $713.05M Estimate, Eps Is Expected In The Range Of $0.80-$1.36 Vs. $1.10 Estimate

Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), a leading North American eyecare pharmaceutical company, today announced an expansion of its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvevye.com%2Fhcp%2Faccessforall&amp;esheet=54236402&amp;newsitemid=20250410793815&amp;lan=en-US&amp;anchor=VEVYE%26%23174%3B+Access+for+All&amp;index=1&amp;md5=0c30859bafbe0396f771bdcc2dff3b9d">VEVYE&#xAE; Access for All</a>("VAFA") program to include patients currently prescribed Klarity-C Drops&#xAE;, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx&#xAE;, Harrow's compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access barriers like prior authorization and reimbursement delays, providing free home delivery, and offering a no‑questions-asked, money-back guarantee.1 The VEVYE Access for All program is flexible, allowing patients to choose to use their insurance coverage2 or take advantage of Harrow's affordable cash price.
As a result of today's announcement, beginning immediately, more than 25,000 patients across the U.S. will be able to convert their Klarity-C prescriptions to VEVYE (cyclosporine ophthalmic solution) 0.1%, an FDA‑approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle (including refills). As a part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer Klarity-C prescriptions to PhilRx in a process that shouldn't take more than 5 minutes.

HROW

Harrow Offers FDA-Approved Dry Eye Treatment for $59 as Klarity-C Patients Transition to VEVYE

–&nbsp;SRC recommended that the trial escalate to the next dose level of 30mg capsule –
–&nbsp;No dose-limiting toxicities (DLT's) or rash observed to date –
MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=bdjA1NLwIvjzxc0iRHV3mB4v_j-fUMSMUZETgEbzbw9DGhfQDg60jTyfo3jTMjiUxCnrP0KAAnCZhTyI0-vCFA97Yjcwk2bnqCtRFYIBunw=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that the external Safety Review Committee recommended that the Company's Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to Cohort 6, 30mg capsule, without modification. This recommendation was based on the review of the safety data from three patients from Cohort 5 and the absence of any dose limiting toxicities (DLT's). In addition, no rash has been observed to date during the DLT period in any of the first 19 patients in either capsule (15 patients) or tablet (four patients) formulation of PAS-004. Rash is a common adverse event (AE) that is observed at low doses with competitor MEK inhibitors and may lead to the discontinuation rate in real world practice.

KTTA

Pasithea Therapeutics: Safety Review Committee Recommends Its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Goldman Sachs analyst Mark Delaney upgrades Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) from Neutral to Buy and lowers the price target from $31 to $27.

Upgrades

Goldman Sachs Upgrades Sensata Technologies to Buy, Lowers Price Target to $27

Needham analyst Serge Belanger reiterates Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) with a Buy and maintains $25 price target.

LQDA

Needham Reiterates Buy on Liquidia, Maintains $25 Price Target

Breakdown of retail sales volumes:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Q1 2025</td>
<td colspan="1" rowspan="1">Q1 2024</td>
<td colspan="1" rowspan="1">Change (%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Retail sales</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">12,304</td>
<td colspan="1" rowspan="1">6,975</td>
<td colspan="1" rowspan="1">+76%</td>
</tr>
</tbody>
</table>
</figure>

PSNY

Polestar Q1 Retail Sales Jump 76% Year-Over-Year To 12,304 Vehicles

Offerings

Fabrinet Filed For Offering Of 381,922 Ordinary Shares By The Selling Securityholder

Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that an oral presentation as well as a poster were presented at the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=vGaHtetDNz_zeU7j37II4m-QXG8fY1eTo96jO1aptZzJPE5uwGaKBIy182yIaOe4HfgMYH3QvLs8vjI1m-XmQ56_nBEdAZGhJGn3l6wtpZ-hBk_ZAkjEr1nQ-_yQzT4oVlviXeKTBPLocdRy3AJDE9W78P3mUfiCITL28ff3G53ZpfjZSn6RlIEHn4s3SDPtSvTzuiO_ufqGEyOwAD_uwnMJO5cAEo75OQgGTVcJEE22NvpEmgN-_NYdsoOODAGuC0_VTkkh1ddtg7DpMNaYYNHJ77hme6cOg0gNApzEIlS6Cjsee8IpwWwwTox1cqwV6UZ7ZyTpJjfvBFeE26C3UiLa0j8gfw-m1epnHzJJnvQb3GA3ZDplXbdku9TiAysXMlbFux4oAAqFclLnnE6NZGhn5SiYcsCDp85o9mUn9R7p_3OgYwcYG1u223keBpYW6-cT6WZEs_24r07cSMV5tH1EID-FlOFTlYSnpy7eUHIeBsA0GPutAdWwHK-ET3gO7kW3BXRSSrgWDf7vsXaYoNtHU7KSFTXEOsKKAe5I7l5Q7XpwFYEm7EtLlvs22VOLpoJSqouZ8Tcjq2qL4qfm2fEJqKbDThd8i5tNXyAJijcQGVbXG-7uC8cFGBGcVYPNg-2mkPzfZn3W55A0gjkLQF1RRImBqrY0LLaD8EWoYMzF3EwTSQHtzv1LkTApIoLw7gs2PADSufqdLhWmx_rE4jI-6NxMFzq8cOUWGZDNnr__i4dtiwNMOtrtfCAS1YWkzPLay_dJd0FiYqGF8E5F2Zf7sNhPfNpqV_hXm5bxP_QHVoLKgDfZLUWCOx2jhp4c">AD/PD&#x2122; 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders</a> held April 1-5, 2025, in Vienna, Austria. The oral presentation outlined new evidence further supporting the disease-modifying activity of GT-02287 in preclinical models of both GBA1 and idiopathic Parkinson's disease (PD). Additionally, the poster presented detailed the design of the ongoing Phase 1b clinical study of GT-02287 in people with Parkinson's disease.
An early biomarker analysis from the currently enrolled participants in the Phase 1b study will be conducted mid-year and will include samples from participants both with and without the GBA1 mutations for purposes of informing Phase 2 planning during the second half of 2025. Complete analysis of the Phase 1b endpoints, available after all patients have completed 90 days of treatment, is anticipated sometime during the fourth quarter of 2025.

GANX

Gain Therapeutics Targets Phase 2 as GT-02287 Phase 1b Biomarker Readout Set for Mid-2025

Goldman Sachs analyst Kash Rangan upgrades BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) from Neutral to Buy and raises the price target from $31 to $34.

Goldman Sachs Upgrades BorgWarner to Buy, Raises Price Target to $34

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $35 price target.

CDTX

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.87 by 13.9 percent. This is a 13.9 percent increase over earnings of $1.87 per share from the same period last year. The company reported quarterly sales of $241.490 million which beat the analyst consensus estimate of $233.954 million by 3.22 percent. This is a 3.60 percent decrease over sales of $250.507 million the same period last year.

Earnings

Earnings Beats

Lovesac Q4 2025 GAAP EPS $2.13 Beats $1.87 Estimate, Sales $241.490M Beat $233.954M Estimate

CLMB

Climb Channel Solutions Partners With Thales To Expand Cybersecurity Offerings

Goldman Sachs analyst Mark Delaney downgrades Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Buy to Neutral and lowers the price target from $103 to $74.

Downgrades

Goldman Sachs Downgrades Visteon to Neutral, Lowers Price Target to $74

Press Releases

SuRo Capital Corp. Reports Second Quarter 2024 Financial Results

SuRo Capital Corp. Third Quarter 2024 Preliminary Investment Portfolio Update

SuRo Capital: Unlocking Access To Potentially High-Growth Venture Opportunities Like OpenAI And Liquid Death

SuRo Capital Corp. to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

SuRo Capital Corp. Reports Third Quarter 2024 Financial Results

SuRo Capital (NASDAQ: SSSS) Allows The Everyday Investor Opportunities In Potentially High Growth Startups Like OpenAI And CoreWeave

SuRo Capital Corp. Fourth Quarter 2024 Preliminary Investment Portfolio Update

SuRo Capital Corp. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 11, 2025

SuRo Capital Corp. Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SuRo Capital Corp. First Quarter 2025 Preliminary Investment Portfolio Update

COUR

LYFT

PLTR

RDDT

SPOT

SSSS

ArrowMark Financial Corp. - Closed End Fund

ArrowMark Financial

Binah Capital Group

Ellington Credit Company Common Shares of Beneficial Interest

Ellington Credit

Great Elm Capital Corp. - Closed End Fund

Great Elm Capital

Great Elm Group

U.S. Global Investors, Inc. - Class A Common Stock

US Global Investors

Heritage Global

Hennessy Advisors

Investcorp Credit Management BDC, Inc. - Common Stock

Investcorp Credit

Innventure

Chicago Atlantic BDC, Inc. - Common Stock

Chicago Atlantic BDC

Logan Ridge Finance Corporation - Common Stock

Logan Ridge Finance

The Marygold Companies, Inc. Common Stock

Marygold Companies

Monroe Capital Corporation - Closed End Fund

Monroe Cap

OFS Credit Company, Inc. - Closed End Fund

OFS Credit Co

OFS Capital Corporation - Closed End Fund

OFS Capital

Oxford Square Capital Corp. - Closed End Fund

Oxford Square Cap

PhenixFIN

Portman Ridge Finance Corporation - Closed End Fund

Portman Ridge Finance

Rand Capital Corporation - Closed End Fund

Rand Capital

Silvercrest Asset Management Group Inc. - Common Stock

Silvercrest Asset Mgmt Gr

Santech Holdings Limited - American Depositary Shares

Santech Holdings

180 Degree Capital Corp. - Closed End Fund

180 Degree Capital

WhiteHorse Finance, Inc. - Closed End Fund

Comments

SuRo Capital

Intérêt court

SuRo Capital (NASDAQ:SSSS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL